Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Nelson, Randy J.

West Virginia University
United States

Mechanism Underlying Sleep Disruption by Mammary Tumors 5R21CA276027-02 Marjorie Perloff, M.D.
Neslund-Dudas, Christine Marie

Henry Ford Health + Michigan State University Health Sciences
United States

HFH-MSU CSRN ACCrual Enrollment and Screening Site 3UG1CA287007-02S1 Elyse LeeVan, M.D., M.P.H.
Nguyen, Sang Minh

Vanderbilt University Medical Center
United States

Gut Microbiome Profiles in Association with Breast Cancer Recurrence and Mortality 1R03CA292953-01 Gabriela Riscuta, M.D., CNS
Nicolson, Fay

Dana-Farber Cancer Inst
United States

SESORRS endoscopy for the staging and evaluation of colorectal cancer 5R00CA266921-04
NINA, BHARDWAJ,

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
United States

Immune determinants modulating cancer development in Lynch Syndrome 1UG3CA290517-01
Noble, Mark D

University Of Rochester
United States

Prevention and treatment of paclitaxel-induced peripheral neuropathy 5R21CA277447-02 Rachel Altshuler, Ph.D.
Noble, Mark D

University Of Rochester
United States

Prevention and treatment of paclitaxel-induced peripheral neuropathy 5R21CA277447-02 Rachel Altshuler, Ph.D.
Nolan, Michael Warren

North Carolina State University Raleigh
United States

Evaluation of TRPM8-expressing neurons as novel regulators of acute radiotherapy-associated pain in patients with head and neck cancer 5R37CA248797-05 Asad Umar, D.V.M., Ph.D.
Nolan, Michael Warren

North Carolina State University Raleigh
United States

Evaluation of TRPM8-expressing neurons as novel regulators of acute radiotherapy-associated pain in patients with head and neck cancer 5R37CA248797-05 Asad Umar, D.V.M., Ph.D.
Nyamathi, Adeline M

University Of California-Irvine
United States

Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India 3R01CA285063-03S2 Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H.
Oberg, Ann Laura

Mayo Clinic Rochester
United States

Management and Data Coordination Unit for PCDC 5U24CA274496-04 Guillermo Marquez, Ph.D.
Ochoa, Augusto C.

Lsu Health Sciences Center
United States

Gulf South Clinical Trials Network (Gulf South NCORP) 3UG1CA189854-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Ochoa, Augusto C.

Lsu Health Sciences Center
United States

Gulf South Clinical Trials Network (Gulf South NCORP) 3UG1CA189854-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Olopade, Olufunmilayo F.

University Of Chicago
United States

The Funding Mechanism of the Pilot Trial 5R01CA276652-03 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Ondrey, Frank G.

University Of Minnesota
United States

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia 5R01CA254270-04 Malgorzata Wojtowicz, M.D.